TwitterLinkedInYouTubeslideshareflickrIFPMA - Global Health Matters - BlogRSS
IFPMA Home

International Federation of Pharmaceutical Manufacturers & Associations




   

Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases

In 2005, the pharmaceutical innovative industry committed, through the endorsement of a Joint Position, to the registration of ongoing clinical trials it sponsored, as well as the outcome of completed clinical trials, on publicly accessible, internet-based registries.

This position highlighted industry’s commitment by providing details such as:

  • Clinical trials concerned
  • Timeframe for posting 
  • Acceptable clinical trials registries
  • Minimum clinical trials registration data set.

As updated in 2009, the Joint industry clinical trials transparency position extended the range of clinical trials that member companies should provide information on to include all clinical trials in patients, as a minimum.

The scope of this Joint Position now includes provisions such as :

  • early stage safety trials of medicines for life-threatening conditions, which are typically not done in healthy volunteers,
  • posting of registry details of all new trials in patients on a publicly accessible website within 21 days of the start of patient enrolment, followed by the
  • posting of summary results of any trial covered by this joint position within one year of the medicinal product concerned being first approved and made commercially available in any country.

Access the full policy document here

 

Joint Position on the Publication of Clinical Trial Results in the Scientific Literature

Recognizing the important role of scientific literature and to expand its transparency policy on clinical trials, the innovative pharmaceutical industry committed in 2010 to principles on the publication of clinical trials data, irrespective of any trial's outcome, in peer-reviewed publications.

Completing the 2005 principles, this new Joint Position details elements on:

  • Concerned scientific literature
  • Content of the information submitted for publication
  • Timeframe for publication
  • Uniform requirements for manuscripts to be followed
  • Disclosure principles of author’s and sponsor’s interest(s)

Access the full policy document here

 

Clinical Trials Portal

 

Get customize clinical trials information using myPortal and receive email alerts on new trials posted matching your defined criteria.
   

Recognizing the important public health benefit for patients and healthcare professionals to access clinical trial information, the pharmaceutical industry agreed in 2005 to develop general principles and guidance on what should be the information disclosed and how to publish such data as laid down in endorsed joint positions.

These Joint Positions set forth the views and commitment of the innovative pharmaceutical industry, as represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Japanese Pharmaceutical Manufacturers Association (JPMA) and the Pharmaceutical Research and Manufacturers of America (PhRMA).

Events
Innovation
IFPMA in External Events
Resources

UPDATED! Developing World Health Partnerships Directory

The research-based pharmaceutical industry engages in a wide range of public-private partnerships...

IFPMA Code of Practice

Expanded IFPMA Code of Practice updates ethical and professional standards for interacting with...